<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kim YJ</submitter><funding>NIA NIH HHS</funding><funding>NIH</funding><pagination>350-358</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8989059</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(4)</volume><pubmed_abstract>Since the introduction of menopausal hormone therapy (MHT) in the 1940s, randomized clinical trials and observational studies have been performed to determine the benefits and risks of MHT. However, MHT therapeutic impact remains under debate as multiple factors including genetic biomarkers and medical history contribute to inter-individual variations in neurodegenerative diseases. Herein, we review the characteristics of women who participated in clinical studies and methodological approaches for study analyses to assess the critical variables influencing an association between MHT and risk of neurodegenerative diseases. Outcomes of the review indicated that: (1) observational studies assessed outcomes of MHT in symptomatic women whereas MHT clinical trials were conducted in asymptomatic </pubmed_abstract><journal>Climacteric : the journal of the International Menopause Society</journal><pubmed_title>Precision hormone therapy: identification of positive responders.</pubmed_title><pmcid>PMC8989059</pmcid><funding_grant_id>R01 AG057931</funding_grant_id><funding_grant_id>R37 AG053589</funding_grant_id><funding_grant_id>1R01AG057931</funding_grant_id><funding_grant_id>P01-AG026572</funding_grant_id><funding_grant_id>P01 AG026572</funding_grant_id><funding_grant_id>R37AG053589</funding_grant_id><pubmed_authors>Brinton RD</pubmed_authors><pubmed_authors>Kim YJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Precision hormone therapy: identification of positive responders.</name><description>Since the introduction of menopausal hormone therapy (MHT) in the 1940s, randomized clinical trials and observational studies have been performed to determine the benefits and risks of MHT. However, MHT therapeutic impact remains under debate as multiple factors including genetic biomarkers and medical history contribute to inter-individual variations in neurodegenerative diseases. Herein, we review the characteristics of women who participated in clinical studies and methodological approaches for study analyses to assess the critical variables influencing an association between MHT and risk of neurodegenerative diseases. Outcomes of the review indicated that: (1) observational studies assessed outcomes of MHT in symptomatic women whereas MHT clinical trials were conducted in asymptomatic </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Aug</publication><modification>2025-04-22T10:53:23.843Z</modification><creation>2024-11-19T21:19:12.969Z</creation></dates><accession>S-EPMC8989059</accession><cross_references><pubmed>33615942</pubmed><doi>10.1080/13697137.2021.1882418</doi></cross_references></HashMap>